CETUXIMAB IN THE FIRST-LINE TREATMENT OF RAS WILD-TYPE METASTATIC COLORECTAL CANCER WITH LIVER-LIMITED DISEASE

被引：1
|
作者：
Souza, P., V [1 ]
Zanini, F. E. [1 ]
Biglia, L., V [1 ]
Kim, H. S. [2 ]
Fahham, L. [2 ]
机构：
[1] Merck, Sao Paulo, Brazil
[2] SENSE Co, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.2578
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN26
引用
收藏
页码：A875 / A875
页数：1
相关论文
共 50 条
  • [21] Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer
    Zekri, Jamal
    Baghdadi, Mohammed Abbas
    Ibrahim, Refaei Belal
    Meliti, Abdelrazak
    Sobahy, Turki M.
    ECANCERMEDICALSCIENCE, 2022, 16 : 1 - 16
  • [22] First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer
    Ohta, Katsuya
    Ikenaga, Masakazu
    Uemura, Mamoru
    Sakata, Kazuya
    Nishimura, Junichi
    Hata, Taishi
    Matsuda, Chu
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Masaki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 216 - 216
  • [23] First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer
    Uemura, Mamoru
    Kim, Ho Min
    Hata, Tsuyoshi
    Sakata, Kazuya
    Okuyama, Masaki
    Takemoto, Hiroyoshi
    Fujii, Hitoshi
    Fukuzaki, Takayuki
    Morita, Tetsushi
    Hata, Taishi
    Takemasa, Ichiro
    Satoh, Taroh
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Maski
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (02) : 375 - 379
  • [24] Noninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer
    Kasper, S.
    Cheng, A-L.
    Overkamp, F.
    Rouyer, M.
    Foch, C.
    Lamy, F-X.
    Esser, R.
    Messinger, D.
    Rothe, V.
    Chen, W.
    Brodowicz, T.
    Zielinski, C. C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] Real-world evidence of efficacy and safety in first-line cetuximab treatment of RAS wild-type metastatic colorectal cancer: A multicenter retrospective study in Taiwan
    Chen, C-C.
    Chang, S-C.
    Chang, Y-Y.
    Lin, B-W.
    Chen, H.
    Hsieh, Y-Y.
    Hsu, H-C.
    Hsieh, M-C.
    Kuan, F-C.
    Wu, C. C.
    Lu, W-C.
    Su, Y-L.
    Liang, Y-H.
    Chen, C.
    Huang, S-Y.
    Wang, C. Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S722 - S722
  • [26] Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial
    Wang, Huijuan
    Huang, Lingfei
    Gao, Peng
    Zhu, Zhengyi
    Ye, Weifeng
    Ding, Haiying
    Fang, Luo
    BMJ OPEN, 2020, 10 (02):
  • [27] A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study
    Kadowaki, Shigenori
    Masuishi, Toshiki
    Ura, Takashi
    Sugiyama, Keiji
    Mitani, Seiichiro
    Narita, Yukiya
    Taniguchi, Hiroya
    Muro, Kei
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (04) : 701 - 707
  • [28] Noninferiority on Overall Survival of Every-2-Weeks vs Weekly Schedule of Cetuximab for First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer
    Kasper-Virchow, Stefan
    Cheng, Ann-Lll
    Overkamp, Friedrich
    Rouyer, Magali
    Foch, Caroline
    Lamy, Francois-Xavier
    Esser, Regina
    Messinger, Diethelm
    Rothe, Vivien
    Chen, Wenfeng
    Brodowicz, Thomas
    Zielinski, Christoph
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 219 - 220
  • [29] A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study
    Shigenori Kadowaki
    Toshiki Masuishi
    Takashi Ura
    Keiji Sugiyama
    Seiichiro Mitani
    Yukiya Narita
    Hiroya Taniguchi
    Kei Muro
    International Journal of Clinical Oncology, 2021, 26 : 701 - 707
  • [30] Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial
    Kasper, Stefan
    Meiler, Johannes
    Knipp, Heike
    Hohler, Thomas
    Reimer, Peter
    Steinmetz, Tilman
    Berger, Winfried
    Linden, Gabriele
    Reis, Henning
    Markus, Peter
    Paul, Andreas
    Dechene, Alexander
    Schumacher, Brigitte
    Kostbade, Karina
    Virchow, Isabel
    Ting, Saskia
    Worm, Karl
    Schmid, Kurt W.
    Herold, Thomas
    Wiesweg, Marcel
    Schuler, Martin
    Trarbach, Tanja
    CLINICAL COLORECTAL CANCER, 2020, 19 (04) : 236 - +
12345